Daiichi Sankyo Company, Limited – Product Pipeline Review

Global Markets Direct’s, ‘Daiichi Sankyo Company, Limited – Product Pipeline Review – 2016’, provides an overview of the Daiichi Sankyo Company, Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Daiichi Sankyo Company, Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Daiichi Sankyo Company, Limited

The report provides overview of Daiichi Sankyo Company, Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Daiichi Sankyo Company, Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Daiichi Sankyo Company, Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Daiichi Sankyo Company, Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Daiichi Sankyo Company, Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Daiichi Sankyo Company, Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Daiichi Sankyo Company, Limited Snapshot 6

Daiichi Sankyo Company, Limited Overview 6

Key Facts 6

Daiichi Sankyo Company, Limited - Research and Development Overview 7

Key Therapeutic Areas 7

Daiichi Sankyo Company, Limited - Pipeline Review 15

Pipeline Products by Stage of Development 15

Pipeline Products - Monotherapy 16

Pipeline Products - Combination Treatment Modalities 17

Pipeline Products - Partnered Products 18

Pipeline Products - Out-Licensed Products 20

Daiichi Sankyo Company, Limited - Pipeline Products Glance 22

Daiichi Sankyo Company, Limited - Late Stage Pipeline Products 22

Daiichi Sankyo Company, Limited - Clinical Stage Pipeline Products 24

Daiichi Sankyo Company, Limited - Early Stage Pipeline Products 27

Daiichi Sankyo Company, Limited - Unknown Stage Pipeline Products 30

Daiichi Sankyo Company, Limited - Drug Profiles 31

A-503451A - Drug Profile 31

CS-1050 - Drug Profile 32

DC-159a - Drug Profile 33

denosumab - Drug Profile 34

DF-461 - Drug Profile 43

Drug to Inhibit IDH1 for Acute Myelocytic Leukemia and Glioma - Drug Profile 44

Drugs for Oncology, Cardiovascular and Metabolic Diseases - Drug Profile 45

DS-1040 - Drug Profile 46

DS-1093 - Drug Profile 47

DS-1123 - Drug Profile 48

DS-1501 - Drug Profile 49

DS-1558 - Drug Profile 50

DS-1971 - Drug Profile 51

DS-2330 - Drug Profile 52

DS-2969 - Drug Profile 53

DS-3032 - Drug Profile 54

DS-3201 - Drug Profile 55

DS-5141 - Drug Profile 56

DS-5272 - Drug Profile 57

DS-5573a - Drug Profile 58

DS-6051 - Drug Profile 59

DS-7080 - Drug Profile 60

DS-8108b - Drug Profile 61

DS-8201 - Drug Profile 62

DS-8273 - Drug Profile 63

DS-8500 - Drug Profile 64

DS-8895 - Drug Profile 66

DS-9001 - Drug Profile 67

DS-9231 - Drug Profile 68

edoxaban tosylate - Drug Profile 69

efatutazone - Drug Profile 74

esaxerenone - Drug Profile 76

etanercept biosimilar - Drug Profile 78

etirinotecan pegol - Drug Profile 81

hydromorphone hydrochloride - Drug Profile 87

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 88

laninamivir - Drug Profile 89

mirogabalin besylate - Drug Profile 93

Monoclonal Antibodies for Undisclosed Indication - Drug Profile 95

Monoclonal Antibody Conjugate to Target HER2 for Breast Cancer - Drug Profile 96

nimotuzumab - Drug Profile 97

patritumab - Drug Profile 101

Pedopeptins to Inhibit LPS for Bacterial Infection - Drug Profile 103

PLX-51107 - Drug Profile 104

PLX-73086 - Drug Profile 105

PLX-7486 - Drug Profile 106

PLX-8394 - Drug Profile 107

PLX-9486 - Drug Profile 108

prasugrel hydrochloride - Drug Profile 109

Protein for Undisclosed Indication - Drug Profile 113

quizartinib dihydrochloride - Drug Profile 114

R-xxx - Drug Profile 121

Small Molecule for Cardiovascular-Metabolic Diseases - Drug Profile 122

Small Molecule for Respiratory Tract Infections - Drug Profile 123

Small Molecule for Tuberculosis - Drug Profile 124

Small Molecule to Agonize Liver X Receptor for Atherosclerosis - Drug Profile 125

Small Molecule to Agonize PPAR Alpha and PPAR Gamma for Metabolic Disorders - Drug Profile 126

Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile 127

Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile 128

Small Molecule to Inhibit HSL for Dyslipidemia - Drug Profile 129

Small Molecule to Inhibit I-KappaB Kinase Beta for Rheumatoid Arthritis - Drug Profile 130

Small Molecule to Inhibit PDE4 for COPD - Drug Profile 131

Small Molecule to Inhibit PDE4B for Lung Inflammation - Drug Profile 132

Small Molecule to Inhibit Renin for Hypertension - Drug Profile 133

Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile 134

Small Molecules for Malaria - Drug Profile 135

Small Molecules for Multiple Neurodegenerative Diseases - Drug Profile 136

Small Molecules for Osteopenia and Osteoporosis - Drug Profile 137

Small Molecules to Agonize BRS-3 for Obesity - Drug Profile 138

Small Molecules to Agonize Pan PPAR for Multiple Sclerosis - Drug Profile 139

Small Molecules to Inhibit FATP1 for Undisclosed Indication - Drug Profile 140

Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases - Drug Profile 141

Small Molecules to Inhibit Nav1.7 for Pain - Drug Profile 142

Small Molecules to Inhibit p53-MDM2 Interaction for Cancer - Drug Profile 143

Sphaerimicin A - Drug Profile 144

SQ-641 - Drug Profile 145

Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile 147

tivantinib - Drug Profile 148

U-31402 - Drug Profile 154

U-3771 - Drug Profile 155

U-3808 - Drug Profile 156

U3-1784 - Drug Profile 157

VN-0102 - Drug Profile 158

VN-0103 - Drug Profile 159

VN-0104 - Drug Profile 160

VN-0105 - Drug Profile 161

VN-100 - Drug Profile 162

Daiichi Sankyo Company, Limited - Pipeline Analysis 163

Daiichi Sankyo Company, Limited - Pipeline Products by Target 163

Daiichi Sankyo Company, Limited - Pipeline Products by Route of Administration 167

Daiichi Sankyo Company, Limited - Pipeline Products by Molecule Type 168

Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action 169

Daiichi Sankyo Company, Limited - Dormant Projects 173

Daiichi Sankyo Company, Limited - Discontinued Pipeline Products 176

Discontinued Pipeline Product Profiles 178

Daiichi Sankyo Company, Limited - Company Statement 183

Daiichi Sankyo Company, Limited - Locations And Subsidiaries 184

Head Office 184

Other Locations & Subsidiaries 185

Appendix 188

Methodology 188

Coverage 188

Secondary Research 188

Primary Research 188

Expert Panel Validation 188

Contact Us 188

Disclaimer 189

List of Tables

List of Tables

Daiichi Sankyo Company, Limited, Key Facts 13

Daiichi Sankyo Company, Limited – Pipeline by Indication, 2016 16

Daiichi Sankyo Company, Limited – Pipeline by Stage of Development, 2016 22

Daiichi Sankyo Company, Limited – Monotherapy Products in Pipeline, 2016 23

Daiichi Sankyo Company, Limited – Combination Treatment Modalities in Pipeline, 2016 24

Daiichi Sankyo Company, Limited – Partnered Products in Pipeline, 2016 25

Daiichi Sankyo Company, Limited – Partnered Products/ Combination Treatment Modalities, 2016 26

Daiichi Sankyo Company, Limited – Out-Licensed Products in Pipeline, 2016 27

Daiichi Sankyo Company, Limited – Out-Licensed Products/ Combination Treatment Modalities, 2016 28

Daiichi Sankyo Company, Limited – Pre-Registration, 2016 29

Daiichi Sankyo Company, Limited – Phase III, 2016 30

Daiichi Sankyo Company, Limited – Phase II, 2016 31

Daiichi Sankyo Company, Limited – Phase I, 2016 32

Daiichi Sankyo Company, Limited – Preclinical, 2016 34

Daiichi Sankyo Company, Limited – Discovery, 2016 36

Daiichi Sankyo Company, Limited – Unknown, 2016 37

Daiichi Sankyo Company, Limited – Pipeline by Target, 2016 171

Daiichi Sankyo Company, Limited – Pipeline by Route of Administration, 2016 174

Daiichi Sankyo Company, Limited – Pipeline by Molecule Type, 2016 175

Daiichi Sankyo Company, Limited – Pipeline Products by Mechanism of Action, 2016 177

Daiichi Sankyo Company, Limited – Dormant Developmental Projects,2016 180

Daiichi Sankyo Company, Limited – Discontinued Pipeline Products, 2016 183

Daiichi Sankyo Company, Limited, Subsidiaries 192

List of Figures

List of Figures

Daiichi Sankyo Company, Limited – Pipeline by Top 10 Indication, 2016 15

Daiichi Sankyo Company, Limited – Pipeline by Stage of Development, 2016 22

Daiichi Sankyo Company, Limited – Monotherapy Products in Pipeline, 2016 23

Daiichi Sankyo Company, Limited – Partnered Products in Pipeline, 2016 25

Daiichi Sankyo Company, Limited – Out-Licensed Products in Pipeline, 2016 27

Daiichi Sankyo Company, Limited – Pipeline by Top 10 Target, 2016 170

Daiichi Sankyo Company, Limited – Pipeline by Route of Administration, 2016 174

Daiichi Sankyo Company, Limited – Pipeline by Top 10 Molecule Type, 2016 175

Daiichi Sankyo Company, Limited – Pipeline Products by Top 10 Mechanism of Action, 2016 176

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports